Company Cannabics Pharmaceuticals Inc. Other OTC
Equities
CNBX
US13764M1009
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Cannabinoid-based Products and Innovative Technologies
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eyal Barad
FOU | Founder | 58 | 15/04/15 |
Gabriel Yariv
CHM | Chairman | 47 | 07/19/07 |
Uri Ben-Or
DFI | Director of Finance/CFO | 52 | 05/16/05 |
- | - | ||
Ilya Reznik
PRN | Corporate Officer/Principal | - | 13/21/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Eyal Barad
FOU | Founder | 58 | 15/04/15 |
Gabriel Yariv
CHM | Chairman | 47 | 07/19/07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,111,352 | 31,111,352 ( 100.00 %) | 0 | 100.00 % |
Company contact information
CNBX Pharmaceuticals, Inc.
No. 3 Bethesda Metro Center Suite 700
20814, Bethesda
+877 424 2429
http://www.cnbxpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.47% | 16.37B | |
+2.23% | 13.58B | |
+27.13% | 11.66B |